Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow NeuroPace Inc

Get SEC filing alerts via email and in your feed for NeuroPace Inc

NPCE

NeuroPace Inc

About NeuroPace Inc

NeuroPace, Inc. develops and commercializes the RNS System, a brain-responsive neuromodulation device for treating drug-resistant focal epilepsy. The system monitors brain activity, recognizes abnormal patterns, and delivers targeted electrical pulses to prevent seizures. It provides clinicians with continuous data, supports personalized therapy, and improves patient outcomes. The company serves adult epilepsy patients, primarily in the U.S., with a focus on expanding indications and markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from NeuroPace Inc

1
1
NeuroPace Inc NeuroPace Reports $22.1 Million Revenue in Q1 2026, Net Loss of $6.7 Million

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
NeuroPace Inc NeuroPace Reports $100M Revenue for 2025, 25% Increase Year-Over-Year

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
NeuroPace Inc NeuroPace Reports 30% Revenue Growth to $27.4 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
NeuroPace Inc NeuroPace Reports 22% Revenue Growth to $23.5 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
NeuroPace Inc NeuroPace Reports 24% Revenue Growth to $22.5 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
NeuroPace Inc NeuroPace Reports $27.1 Million Net Loss and 22% Revenue Growth in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
NeuroPace Inc NeuroPace Reports 28% Revenue Growth, Reduced Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments